Lactobacillus plantarum PDA6 Neurotransmitter Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for anxiety disorders and depression, such as benzodiazepines, have short-term effects and are associated with severe side effects and dependency, limiting their use as first-line medications due to their impact on GABA and 5-HT receptors.
Innovation Solution
A novel Lactobacillus plantarum strain, Lactobacillus plantarum PDA6, with neurological effects, is used to treat anxiety disorders and depression by increasing expression of BDNF, 5-HT, and GABA, potentially offering fewer side effects and longer-term benefits when administered as a pharmaceutical or nutraceutical composition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs (benzodiazepines) are used to treat anxiety disorders by targeting GABA and 5-HT receptors, then anxiety symptoms are reduced, but side effects (daytime fatigue, sleepiness, dry mouth, nausea, uncoordinated movements) and dependency increase
Solution Approach 1:
The patent uses Lactobacillus plantarum PDA6 as an intermediary organism that indirectly affects neurotransmitter systems. Instead of directly targeting GABA or 5-HT receptors with pharmaceutical compounds, the probiotic strain modulates the gut-brain axis through metabolic products and neural signaling, thereby reducing anxiety symptoms while avoiding the direct receptor binding that causes side effects and dependency
Solution Approach 2:
The patent replaces the mechanical/pharmacological approach of direct receptor binding with a biological approach using probiotic metabolism. The Lactobacillus plantarum PDA6 strain produces neurotransmitters (GABA, 5-HT) and metabolites that signal to the brain through the vagus nerve and other pathways, substituting direct drug-receptor interaction with a complex biological communication system that avoids traditional drug side effects
2Duration of action of stationary object
If conventional drugs are used for long-term treatment of anxiety disorders, then sustained symptom management is achieved, but dependency and cumulative side effects worsen
Solution Approach 1:
The Lactobacillus plantarum PDA6 probiotic strain establishes itself in the gut microbiota and continues to produce beneficial metabolites and neurotransmitters autonomously over time. Once colonized, the probiotic serves itself by maintaining its population and continuously generating therapeutic effects without requiring external drug supplementation, thereby providing long-term treatment without dependency
Solution Approach 2:
The patent changes the fundamental parameter of treatment from exogenous pharmaceutical compounds to endogenous probiotic organisms. By introducing Lactobacillus plantarum PDA6 that colonizes the gut and continuously produces neurotransmitters and metabolites, the treatment transitions from temporary drug effects to sustained biological function, extending treatment duration while avoiding cumulative side effects
Data Source
AI summary
Provided are a Lactobacillus plantarum strain, Lactobacillus plantarum PDA6, and a composition thereof. Also provided are methods using Lactobacillus plantarum PDA6 or a composition thereof for treating anxiety disorder or depression.